Prognostic value of intratumoral Fusobacterium nucleatum and association with immune-related gene expression in oral squamous cell carcinoma patients.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
12 04 2021
12 04 2021
Historique:
received:
26
07
2020
accepted:
02
03
2021
entrez:
13
4
2021
pubmed:
14
4
2021
medline:
9
11
2021
Statut:
epublish
Résumé
Changes in the oral microbiome, particularly Fusobacterium nucleatum, are associated with oral squamous cell carcinoma (OSCC). F. nucleatum has been reported to modulate local immunity in cancers. We aimed to assess the association between intratumoral F. nucleatum and clinico-pathological features, relapse, and overall survival (OS) in two independent cohorts of patients with OSCC, and to explore the interplay with immune-related genes. We retrospectively analyzed tissue samples from a first cohort of 122 patients with head and neck squamous cell carcinoma, including 61 OSCC (cohort #1), and a second cohort of 90 additional OSCC (cohort #2). We then performed a sensitivity analysis on the merged cohort of OSCC patients (N = 151). F. nucleatum 16S rRNA gene sequences were quantified using real-time quantitative PCR. The presence of gram-negative bacteria and macrophages was confirmed by LPS and CD163 immunostainings, respectively. F. nucleatum positivity was associated with older age, less alcohol and combined alcohol plus tobacco consumption, and less frequent lymph node invasion. There was a trend for a lower recurrence rate in F. nucleatum-positive cases, with less metastatic relapses compared to F. nucleatum-negative tumors, and significantly longer OS, relapse-free and metastasis-free survival. F. nucleatum status was independently associated with OS in multivariate analysis. Immune-related gene and immunohistochemistry analyses showed that gram-negative bacteria load inversely correlated with M2 macrophages. F. nucleatum-associated OSCC has a specific immune microenvironment, is more frequent in older, non-drinking patients, and associated with a favorable prognosis.
Identifiants
pubmed: 33846399
doi: 10.1038/s41598-021-86816-9
pii: 10.1038/s41598-021-86816-9
pmc: PMC8041800
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7870Références
Technol Cancer Res Treat. 2019 Jan 1;18:1533033819867354
pubmed: 31370775
Endocr Relat Cancer. 2004 Sep;11(3):489-95
pubmed: 15369450
J Immunol. 2007 Jan 15;178(2):970-5
pubmed: 17202359
Ann Oncol. 2014 Nov;25(11):2101-2115
pubmed: 25057165
Comput Struct Biotechnol J. 2020 Mar 13;18:631-641
pubmed: 32257046
Eur J Cancer. 2019 Nov;121:210-223
pubmed: 31593831
Sci Rep. 2017 Sep 18;7(1):11773
pubmed: 28924229
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Int Immunopharmacol. 2019 Sep;74:105724
pubmed: 31272064
Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):541-50
pubmed: 19190158
JNCI Cancer Spectr. 2019 Jan 07;2(4):pky045
pubmed: 31360870
Oncoimmunology. 2019 Mar 27;8(6):e1581531
pubmed: 31069151
Cancer Immunol Immunother. 2018 Oct;67(10):1635-1646
pubmed: 30121899
Oncotarget. 2016 Jul 26;7(30):47418-47430
pubmed: 27329726
Cancers (Basel). 2020 Oct 08;12(10):
pubmed: 33049910
Gastroenterology. 2017 Mar;152(4):851-866.e24
pubmed: 27876571
Oral Oncol. 2019 Jun;93:66-75
pubmed: 31109698
N Engl J Med. 2020 Jan 2;382(1):60-72
pubmed: 31893516
Nat Rev Clin Oncol. 2018 Jun;15(6):382-396
pubmed: 29636538
Nat Rev Immunol. 2001 Nov;1(2):135-45
pubmed: 11905821
Transl Oncol. 2019 Jun;12(6):846-851
pubmed: 30986689
Int J Cancer. 2019 Aug 1;145(3):775-784
pubmed: 30671943
Front Oncol. 2019 Jul 23;9:656
pubmed: 31396482
Nat Rev Cancer. 2018 May;18(5):269-282
pubmed: 29497144
Oral Maxillofac Surg Clin North Am. 2014 May;26(2):123-41
pubmed: 24794262
Front Microbiol. 2019 Jun 26;10:1439
pubmed: 31297102
Clin Cancer Res. 2006 Jan 15;12(2):465-72
pubmed: 16428488
Cancers (Basel). 2020 Sep 30;12(10):
pubmed: 33008024
Front Microbiol. 2018 May 03;9:862
pubmed: 29774014
Chronic Dis Transl Med. 2019 Oct 01;5(3):178-187
pubmed: 31891129
Science. 2020 May 29;368(6494):973-980
pubmed: 32467386
Sci Transl Med. 2015 Jan 21;7(271):271ps1
pubmed: 25609166
Front Oncol. 2019 Jul 03;9:566
pubmed: 31334107
Nature. 2007 Oct 18;449(7164):804-10
pubmed: 17943116
World J Gastroenterol. 2016 Jan 14;22(2):557-66
pubmed: 26811607
Cancer Epidemiol Biomarkers Prev. 2020 Mar;29(3):539-548
pubmed: 31915144
J Immunol. 2010 Mar 1;184(5):2518-27
pubmed: 20100933
Eur J Cancer. 2013 Mar;49(4):769-81
pubmed: 23122780
Clin Vaccine Immunol. 2012 Jul;19(7):1093-101
pubmed: 22623652
Arch Oral Biol. 2020 Apr;112:104669
pubmed: 32028171
Medicine (Baltimore). 2020 Apr;99(15):e19698
pubmed: 32282725
Oncoimmunology. 2020 May 13;9(1):1754094
pubmed: 32934875
PLoS One. 2017 Oct 9;12(10):e0186179
pubmed: 29016688
Immunity. 2015 Feb 17;42(2):344-355
pubmed: 25680274